Navigation Links
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead Research Corporation (NASDAQ:ARWR) announced today that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate.

Calando is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to create new, targeted siRNA therapeutics. Its lead anti-cancer therapeutic candidate contains a linear cyclodextrin polymer, the siRNA, and a targeting agent. The formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum. One important result of the study was the lack of a significant immune response to the siRNA, demonstrating that the formulation is well tolerated at doses much higher than those previously shown to have anti-cancer effects. Calando is expecting to enter clinical trials with this formulation later this year.

Further information about Calando and the study can be found at www.calandopharma.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/6/2009)...N.C., Nov. 6 Chimerix, Inc., a bio...antiviral therapeutics to address life-threatening... the company,s lead antiviral compound, CMX001, to...l Health Security Initiative (GHSI). CMX001 is a ... the treatment of smallpox, as well as other serio...
(Date:11/6/2009)...ire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin...anta-based, biopharmaceutical company developing h...Immunodeficiency Virus) and other infectious agent...l results and provided an operational update. ,...tive Officer commented, "We are pleased with our p...
(Date:11/6/2009)...ire-FirstCall/ -- Caraco Pharmaceutical Laboratori... tromethamine ophthalmic solution, 0.5% following ...tration (FDA) for Sun Pharma,s Abbreviated New Dru...almic solution on the first day following patent e...ically equivalent to Acular® Ophthalmic Solut...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 51313 1Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 51313 2Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 51310 1Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 51310 2Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 51310 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3
... Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Comp...discovery and development of novel antibiotics for... announced today that company,representatives are ...,week., Gordon Research Conference on Medicinal C... Senior Scientist, presented at the Gordon,Researc...
...n-Whites New to Antiretroviral Therapy Respond ...XICO CITY, Aug. 5 Initial treatment,regimens cont...s (NYSE:,ABT) protease inhibitor Kaletra(R) (lopin...r controlling the virus (reducing the amount of HI...D4 cells) in women compared to,men and in non-whit...
Other Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8
(Date:11/7/2009)...wswire-USNewswire/ -- The American Medical Associa...ard for Citizenship and Community Service to Manus...IL. The award recognizes physicians who have gone ...o make an outstanding public service contribution ...ward today during the opening session of the 2009 ...
(Date:11/7/2009)...(CT), David A. Cook (GA), Louis J. Goodman (TX), P... ,, CHICAGO, Nov. 7 ...nted five medical society executive leaders with a...the goals and ideals of the medical profession. Th...olicy making meeting in Houston. ,, (Logo: h...
(Date:11/7/2009)...swire-USNewswire/ -- Members of the AMA are trying...solution rescinding the AMA,s support of HR 3962. ... responsible to their PATIENTS, not the leadership...icy for the Association of American Physicians and...other medical groups. ,, "If the AMA leadershi...
(Date:11/7/2009)...holics have a responsibility to vigorously oppose ...uo." ,, WASHINGTON, Nov. 7 /PRNewswire-USNe...rown released the following statement on the news ...ancy Pelosi,s Affordable Health Care for America A...he status quo for abortion is voted upon. ,, "...
(Date:11/7/2009)...Newswire-USNewswire/ -- Speaker Nancy Pelosi and D...fternoon following a Democratic Whip meeting with ...are the Speaker,s opening remarks: ,, "Thank y...ion for us to receive the President of the United ...with our vote and making progress for the American...
Breaking Medicine News(10 mins):Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...I-guided breast biopsy successfully removed the br...as slices of the lesion, according to radiologists...ng increasingly useful in patients with lesions th...cer Center in Houston. "However, it is hard to con...
...chiatrist with the Providence Veterans Affairs Med...t a new care model for treating bipolar disorder i...ber of maniac episodes suffered by them. In a rand... affects nearly 6 million Americans each year. The...
...ding to a study by researchers from Texas A&M Univ...new cause for obesity in children.// Dr. Ale... of sociology with a research appointment from Tex...spent with them. "Parental Time, Role Strain...
... is the largest producer of milk in the world but ...growing children being the worst deprived, parliam... availability of milk in India is 229 gm per day a...re Taslimuddin told the Rajya Sabha that India pro...
...nued reports of illness caused by eating raw shell...on to issue a warning today against eating raw she...clams raised in the Pacific Northwest have made pe...sh. The illness is caused by Vibrio parahaemolytic...
...rchers from University of North Carolina at Chapel...sponsible for degrading proteins in Cystic Fibrosi...teins to regain their shape and thus may herald in...ein cystic fibrosis transmembrane conductance regu...
Other Medicine News:Health News:MRI-guided Breast Biopsy Pronounced a Success 2Health News:Promising Care Model For Bipolar Disorder 2Health News:Parental Time Influences Children’s Nutritio 2Health News:Parental Time Influences Children’s Nutritio 3Health News:Parental Time Influences Children’s Nutritio 4Health News:Cellular System Causing Destruction Of Faulty Proteins In Cystic Fibrosis Identified 2
...ight system with streamlined therapeutic capacitie...sity (50 mW/cm) of its elder brother Excilite, but...ssesses the latest in technology, in order to sati...tem is fitted with additional screens which may be...
...gle wavelength of 1064nm, available in two version... W or 100 W, and it is a valid ally in all-mini-in...sical version of Smart1064 family and it is the mo...d like to have a versatile system for interdiscipl...
SmartLipo
Hiro 1.0
Medicine Products: